Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Medience Co., Ltd. (014100:KRX), powered by AI.
Medience Co., Ltd. is currently trading at ₩1,680. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Medience Co., Ltd. on Alpha Lenz.
Medience Co., Ltd.'s P/E ratio is -3.3.
“Medience Co., Ltd. trades at a P/E of -3.3 (undervalued) with modest ROE of -8.5%.”
Ask for details →Medience Co., Ltd. is a prominent player in the pharmaceutical and healthcare industry. The company specializes in the manufacture and distribution of high-quality healthcare products and medical devices, primarily aimed at enhancing health and well-being. With its diverse product portfolio, Medience Co., Ltd. serves both domestic and international markets, contributing significantly to the global healthcare supply chain. The organization’s offerings include over-the-counter medicines, nutritional supplements, and specialized medical equipment, addressing the needs of healthcare providers and patients alike. Medience Co., Ltd. is renowned for its commitment to innovation, continually investing in research and development to deliver cutting-edge solutions that meet the ever-evolving demands of the healthcare sector. Its market presence is further bolstered by strong partnerships and collaborations with other key players in the industry, underpinning its role as a vital contributor to public health infrastructure. Headquartered in South Korea, Medience Co., Ltd. plays an influential role in advancing healthcare standards and ensuring the availability of essential medical and wellness products worldwide.
“Medience Co., Ltd. trades at a P/E of -3.3 (undervalued) with modest ROE of -8.5%.”
Ask for details →Medience Co., Ltd. (ticker: 014100) is a company listed on KRX in the Consumer Defensive sector (Household & Personal Products). It has approximately 96 employees. Market cap is $19.8B.
The current price is ₩1,680 with a P/E ratio of -3.29x and P/B of 0.29x.
ROE is -8.48% and operating margin is -2.26%. Annual revenue is $48.8B.